NYT picks apart ADHD

Share this article:

The New York Times gives a clinical and marketing look at the uptick in the $9-billion dollar attention deficit disorder market. Among the topics covered are the nomenclature for one of the condition's hallmark drugs—Adderall, which was a combination of A.D.D. and All—and the professional and consumer marketing strategies that have helped cultivate a prescriptive landscape that psychiatrist Keith Conners tells the Gray Lady “make it look like an epidemic. Well, it's not. It's preposterous.”

The piece also touches on the prickly topic of pharmaceutical-sponsored speaking engagements (one industry-compensated orator says company money has not influenced his research) and patient-facing materials about ADHD surfacing in at least one school system as well as the relatively recent wave of adult ADHD awareness messaging, among other topics.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.